SBIR PHASE I TOPIC #439 - ADVANCED SAMPLE PROCESSING PLATFORMS FOR DOWNSTREAM SINGLE-CELL MULTI-OMIC ANALYSIS

SBIR 第一阶段主题

• 批准号: 10724107
• 负责人: QI ZHAO
• 金额: $ 39.98万
• 依托单位: ENRICH THERAPEUTICS, INC.
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-19 至 2023-09-18
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10724107
• 关键词: Cell Line; Cell Separation; Cells; Digestion; Dissociation; Genomics; Goals; Hand; Human; Image; Individual; Libraries; Liver neoplasms; Manuals; Maps; Monitor; Mus; Phase; Protocols documentation; Reagent; Research Design; Resistance; Retrieval; Running; Sampling; Site; Small Business Innovation Research Grant; Time; Tissues; Tumor Tissue; Validation; base; human tissue; multiple omics; operation; pancreatic neoplasm; real-time images; tumor

The long term goal of this proposal is to develop a fast, hands-free platform that integrates tissue dissociation, clone characterization and isolation to support the growing field of single celll multiomics. During the phase I of the proposal, enrich will adapt the exiting image based, debris-resistant clone isolation machine by developing essential reagents, protocols and consumables for in-place tissue dissociation, multicriteria single cell isolation and lossless single cell retrieval. Efficiency of tissue digestion, single cell capture, washing and retrieval will be tightly monitored by existing real-time imaging functionality. Adequate and high viability single cells from human liver and pancreas tumors will be isolated and scRNA and scDNA sequencing libraries of each sample will be prepared by 10xGenomics platform and submitted for Illumina sequencing. The validation will be achieved by an array of metrics including total operation time, level of manual intevention, single cell yield and quality and sc sequence mappability. if successful, a multi-site, tumor type study will be performed in the next phase.

该提案的长期目标是开发一个快速，免提的平台，该平台整合组织分离，克隆表征和隔离，以支持单细胞多组学的增长领域。在该提案的第一阶段中，Enrich将通过开发基于基于碎片的克隆隔离机的疏远，通过开发基本试剂，方案和消耗品，以进行原位组织解离，多标准单细胞隔离和无损单细胞检索。现有的实时成像功能将严格监测组织消化，单细胞捕获，洗涤和检索的效率。将分离出来自人类肝脏和胰腺肿瘤的足够且高的生存能力单细胞，每个样品的SCRNA和SCDNA测序文库将由10x基因组平台制备，并提交用于Illumina测序。验证将通过一系列指标来实现，包括总操作时间，手动无知水平，单细胞产量和质量以及SC序列映射性。如果成功，将在下一阶段进行多部位的肿瘤类型研究。